Inebilizumab
Uplizna (inebilizumab) is a prescription monoclonal antibody medication designed to reduce the frequency of attacks in adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who test positive for anti-aquaporin-4 (AQP4) antibodies. It works by targeting and depleting CD19-positive B cells, which play a key role in the inflammatory process that damages the optic nerves and spinal cord in NMOSD.
Uplizna is a B-cell depleting therapy used to treat adults with NMOSD, a rare autoimmune condition affecting the optic nerves and spinal cord.
Key facts at a glance
- RxNorm
- 2373956
- Generic
- Uplizna
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Uplizna is FDA-approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are seropositive for anti-aquaporin-4 (AQP4) antibodies. NMOSD is a rare autoimmune disorder where the immune system attacks the optic nerves and spinal cord, causing vision loss, weakness, numbness, and paralysis.
Uplizna is a CD19-directed cytolytic antibody that binds to CD19, a protein found on the surface of B cells. By binding to CD19, it causes depletion of B cells through antibody-dependent cellular cytotoxicity and other mechanisms, thereby reducing the autoimmune attack on the central nervous system characteristic of NMOSD.
Uplizna is administered as an intravenous infusion by a healthcare provider. Common side effects include urinary tract infection, infusion reactions, and fatigue. Serious risks include serious infections, potential for hypogammaglobulinemia, and infusion reactions. Patients should be monitored for infections during and after treatment. Live vaccines should be avoided during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy